Cargando…

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Detalles Bibliográficos
Autores principales:	Karachaliou, Niki, Codony-Servat, Jordi, Teixidó, Cristina, Pilotto, Sara, Drozdowskyj, Ana, Codony-Servat, Carles, Giménez-Capitán, Ana, Molina-Vila, Miguel Angel, Bertrán-Alamillo, Jordi, Gervais, Radj, Massuti, Bartomeu, Morán, Teresa, Majem, Margarita, Felip, Enriqueta, Carcereny, Enric, García-Campelo, Rosario, Viteri, Santiago, González-Cao, María, Morales-Espinosa, Daniela, Verlicchi, Alberto, Crisetti, Elisabetta, Chaib, Imane, Santarpia, Mariacarmela, Luis Ramírez, José, Bosch-Barrera, Joaquim, Felipe Cardona, Andrés, de Marinis, Filippo, López-Vivanco, Guillermo, Miguel Sánchez, José, Vergnenegre, Alain, Sánchez Hernández, José Javier, Sperduti, Isabella, Bria, Emilio, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984426/ https://www.ncbi.nlm.nih.gov/pubmed/36869103 http://dx.doi.org/10.1038/s41598-023-30374-9

Ejemplares similares

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Jacobsen, Kirstine, et al.
Publicado: (2017)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
por: Karachaliou, Niki, et al.
Publicado: (2018)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
por: Chaib, Imane, et al.
Publicado: (2017)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
por: Ito, Masaoki, et al.
Publicado: (2019)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
por: Codony-Servat, Jordi, et al.
Publicado: (2020)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2020)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
por: Ito, Masaoki, et al.
Publicado: (2020)

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
por: Santarpia, Mariacarmela, et al.
Publicado: (2011)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot
por: Pall, Gurman Singh, et al.
Publicado: (2007)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Advances in immunotherapy for treatment of lung cancer
por: Bustamante Alvarez, Jean G., et al.
Publicado: (2015)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from in vitro studies
por: Albuquerque, Catarina, et al.
Publicado: (2021)

Tumor immune microenvironment characterization and response to anti-PD-1 therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2015)

Activation of viral defense signaling in cancer
por: Gonzalez-Cao, Maria, et al.
Publicado: (2018)

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
por: Bonanno, Laura, et al.
Publicado: (2016)

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
por: Simonetti, Sara, et al.
Publicado: (2010)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Well Water as a Possible Source of Waddlia chondrophila Infections
por: Codony, Francesc, et al.
Publicado: (2012)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response
por: Gonzalez-Cao, Maria, et al.
Publicado: (2016)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
por: Aguado, Cristina, et al.
Publicado: (2018)

Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse
por: Domingo-Domenech, J, et al.
Publicado: (2005)

Commentary: Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis
por: Agustí, Gemma, et al.
Publicado: (2018)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)

Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer
por: Codony, Victoria L., et al.
Publicado: (2021)

Human endogenous retroviruses and cancer
por: Gonzalez-Cao, María, et al.
Publicado: (2016)

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening
por: Rosell, Rafael, et al.
Publicado: (2015)

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
por: Nilsson, R. Jonas A., et al.
Publicado: (2015)

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
por: Karachaliou, Niki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ggf7786k6ku4bbk0ecmk5qf6vf